[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
Identifieur interne : 001105 ( PubMed/Curation ); précédent : 001104; suivant : 001106[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
Auteurs : N V FedorovaSource :
- Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [ 1997-7298 ] ; 2003.
English descriptors
- KwdEn :
- Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Dopamine Agents (administration & dosage), Dopamine Agents (therapeutic use), Dopamine Agonists (administration & dosage), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Drug Therapy, Combination, Humans, Levodopa (administration & dosage), Levodopa (therapeutic use), Parkinson Disease (drug therapy), Piribedil (administration & dosage), Piribedil (adverse effects), Piribedil (therapeutic use), Placebos, Time Factors, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Dopamine Agents, Dopamine Agonists, Levodopa, Piribedil.
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists, Piribedil.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agents, Dopamine Agonists, Levodopa, Piribedil.
- drug therapy : Parkinson Disease.
- Drug Therapy, Combination, Humans, Placebos, Time Factors, Treatment Outcome.
Abstract
The study of 99 patients has been conducted in 5 Russian centers. Pronoran ("Servier", France) combined with levodopa was used in dosage 50-150 mg daily during 6 months. The treatment was placebo-controlled. Significant differences (p < 0.001) between the study and control groups in expression of all main symptoms of the disease were found.
PubMed: 14681961
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001146
Links to Exploration step
pubmed:14681961Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].</title>
<author><name sortKey="Fedorova, N V" sort="Fedorova, N V" uniqKey="Fedorova N" first="N V" last="Fedorova">N V Fedorova</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:14681961</idno>
<idno type="pmid">14681961</idno>
<idno type="wicri:Area/PubMed/Corpus">001146</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001146</idno>
<idno type="wicri:Area/PubMed/Curation">001105</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001105</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].</title>
<author><name sortKey="Fedorova, N V" sort="Fedorova, N V" uniqKey="Fedorova N" first="N V" last="Fedorova">N V Fedorova</name>
</author>
</analytic>
<series><title level="j">Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</title>
<idno type="ISSN">1997-7298</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Dopamine Agents (administration & dosage)</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Dopamine Agonists (administration & dosage)</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Piribedil (administration & dosage)</term>
<term>Piribedil (adverse effects)</term>
<term>Piribedil (therapeutic use)</term>
<term>Placebos</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
<term>Dopamine Agonists</term>
<term>Levodopa</term>
<term>Piribedil</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Piribedil</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
<term>Dopamine Agonists</term>
<term>Levodopa</term>
<term>Piribedil</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Placebos</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The study of 99 patients has been conducted in 5 Russian centers. Pronoran ("Servier", France) combined with levodopa was used in dosage 50-150 mg daily during 6 months. The treatment was placebo-controlled. Significant differences (p < 0.001) between the study and control groups in expression of all main symptoms of the disease were found.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14681961</PMID>
<DateCreated><Year>2003</Year>
<Month>12</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted><Year>2004</Year>
<Month>05</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>10</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1997-7298</ISSN>
<JournalIssue CitedMedium="Print"><Volume>103</Volume>
<Issue>11</Issue>
<PubDate><Year>2003</Year>
</PubDate>
</JournalIssue>
<Title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</Title>
<ISOAbbreviation>Zh Nevrol Psikhiatr Im S S Korsakova</ISOAbbreviation>
</Journal>
<ArticleTitle>[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].</ArticleTitle>
<Pagination><MedlinePgn>21-4</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The study of 99 patients has been conducted in 5 Russian centers. Pronoran ("Servier", France) combined with levodopa was used in dosage 50-150 mg daily during 6 months. The treatment was placebo-controlled. Significant differences (p < 0.001) between the study and control groups in expression of all main symptoms of the disease were found.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fedorova</LastName>
<ForeName>N V</ForeName>
<Initials>NV</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D018848">Controlled Clinical Trial</PublicationType>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
</PublicationTypeList>
<VernacularTitle>Primenenie pronorana (piribedila) pri bolezni Parkinsona: rezul'taty mul'titsentrovogo issledovaniia.</VernacularTitle>
</Article>
<MedlineJournalInfo><Country>Russia (Federation)</Country>
<MedlineTA>Zh Nevrol Psikhiatr Im S S Korsakova</MedlineTA>
<NlmUniqueID>9712194</NlmUniqueID>
<ISSNLinking>1997-7298</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>DO22K1PRDJ</RegistryNumber>
<NameOfSubstance UI="D010891">Piribedil</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010891" MajorTopicYN="N">Piribedil</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year>
<Month>12</Month>
<Day>20</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>5</Month>
<Day>15</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2003</Year>
<Month>12</Month>
<Day>20</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">14681961</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001105 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001105 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:14681961 |texte= [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:14681961" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |